Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on November 14, 2019. The report details a material definitive agreement entered into on November 11, 2019, regarding the company's principal executive offices in Woburn, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a lease amendment and contains no financial performance data.
Material Changes
The primary material change reported is the execution of a First Amendment to the company's Woburn Lease with ARE-MA REGION NO. 20, LLC. Key terms of this amendment include:
- Space Expansion: An increase of approximately 7,550 square feet to the leased space.
- Term Extension: The lease term has been extended by three years, now running through February 2025.
Outlook, Risks, and Management Commentary
Management commentary is limited to the description of the lease expansion and extension. The filing does not contain forward-looking guidance, specific risk factors, contingencies, or unusual items beyond the operational change of securing additional office space.
Investor Verification Checklist
- Verify the total square footage of the new lease and the associated monthly rent increase.
- Confirm the total remaining lease obligation and any potential early termination penalties.
- Review the company's cash position to ensure it can support the expanded facility costs.
- Check subsequent filings for any further amendments to the Woburn Lease.